ACTUATE THERAPEUTICS, INC. cotiza a 0.47 USD y tiene una capitalización bursátil de $11M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.24 | $-0.18 |
| Estimado | $-0.17 | $-0.20 | $-0.21 | $-0.24 |
| Sorpresa | — | — | -14.3% | +25.0% |
| Métrica | ACTU | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -280.5% | -40.4% | -240.1% |
| ROA | -158.4% | -32.0% | -126.4% |
| Current Ratio | 2.39 | 2.84 | -0.45 |
| Debt / Equity | — | 0.28 | — |